SSY GROUP (02005.HK): Obtains production registration approval for sodium ozagrel injection, achieving full dosage form coverage

NewTimeSpace News: On 25 August 2026, SSY Group Limited (stock code: 02005) announced that the Group has obtained production registration approvals from the National Medical Products Administration of China for sodium ozagrel injection (5ml:40mg and 2.5ml:20mg), which is classified as chemical drug Category 3 and deemed to have passed the consistency evaluation.

The announcement stated that sodium ozagrel injection is mainly used for the treatment of acute thrombotic cerebral infarction and movement disorders accompanying cerebral infarction. The Group has already obtained approvals for two large-volume infusion specifications of sodium ozagrel and sodium chloride injection (250ml:80mg and 100ml:80mg), and the latest approval achieves full dosage form coverage of sodium ozagrel, combining small-volume injections and sodium chloride large-volume infusions, which will help the Group further expand into the neurology market.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.